Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
alemtuzumab GZ402673 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| alemtuzumab (subcutaneous injection) | EXPERIMENTAL | Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine \[loratadine, cetirizine, dexchlorpheniramine\], paracetamol, acyclovir) will be administered prior alemtuzumab administration. |
| alemtuzumab (intravenous infusion) | EXPERIMENTAL | Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine \[loratadine, cetirizine, dexchlorpheniramine\], paracetamol, acyclovir) will be administered prior alemtuzumab administration. |
| Name | Type | Description |
|---|---|---|
| Acyclovir | DRUG | Pharmaceutical form:tablet Route of administration: oral |
| Methylprednisolone | DRUG | Pharmaceutical form:tablet Route of administration: oral |
| alemtuzumab GZ402673 | DRUG | Pharmaceutical form:solution for infusion Route of administration: intravenous |
| Paracetamol | DRUG | Pharmaceutical form:tablet Route of administration: oral |
| Loratadine | DRUG | Pharmaceutical form:tablet Route of administration: oral |
| Ceterizine | DRUG | Pharmaceutical form:tablet Route of administration: oral |
| Dexchlorpheniramine | DRUG | Pharmaceutical form:tablet Route of administration: oral |
Inclusion criteria: * Male or female adults with a diagnosis of Multiple Sclerosis (MS) based on 2010 revision of McDonald criteria. * Diagnosis of progressive MS including primary progressive MS and secondary progressive MS. * Age ≥18 years. * Signed informed consent form. * Covered by a health in...
Alemtuzumab GZ402673 is an investigational small molecule being studied for the treatment of progressive multiple sclerosis, a form of multiple sclerosis characterized by steadily worsening neurological function. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Alemtuzumab GZ402673 is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol SNY. The drug is currently in early-stage clinical development for progressive multiple sclerosis.
Alemtuzumab GZ402673 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 study has been completed, but the drug remains in early-stage testing and is not yet available to patients outside of clinical trials.
Alemtuzumab GZ402673 has one completed clinical trial, identified as NCT02583594. This Phase 1 study, titled 'A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,' enrolled 24 participants in Spain. The trial was controlled but not double-blinded.
Alemtuzumab GZ402673 is a distinct investigational drug being developed by Sanofi for progressive multiple sclerosis. While its name includes 'alemtuzumab,' it is a small molecule, unlike the monoclonal antibody alemtuzumab used for other conditions. It is currently in Phase 1 trials and is not approved.